Literature DB >> 7497676

Giant cell tumor of bone. Curettage and cement reconstruction.

S A Bini1, K Gill, J O Johnston.   

Abstract

A retrospective review was conducted of all consecutive giant cell tumors treated by the senior author (JOJ) between 1975 and 1990 using the technique of aggressive curettage through a large bone window followed by acrylic cement reconstruction. Steinmann pins were used as reinforcement bars within the methacrylate in large lesions. Thirty-eight patients with a mean followup of 5.2 years (range, 2-16 years) were identified. Three (8%) recurrences are reported. There were no infections or mechanical failures of the construct. Functional results were good to excellent in 84% of patients. Ninety-five percent of patients reported good or excellent stability, no deformity, and emotional acceptance of the procedure. The recurrence rate with this protocol (8%) approached that associated with wide resection or amputation (0%-5%), and was lower than that seen with simple curettage and bone grafting (27%-55%). Acrylic cement reconstruction is a safe and effective procedure that provides local adjuvant therapy and immediate stability for early rehabilitation. The authors emphasize the importance of aggressive curettage of the lesion through a large bone window and suggest the use of reinforcement bars within the cement for large defects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497676

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  39 in total

1.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

2.  Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results.

Authors:  K Szalay; I Antal; J Kiss; M Szendroi
Journal:  Int Orthop       Date:  2006-09-13       Impact factor: 3.075

3.  Orthopaedic . Radiology . Pathology Conference: Painful distal femur Lesion in a 13-year-old girl.

Authors:  Asheesh Harsha; Camilo E Villalobos; Leon D Rybak; Dariusz Borys; James C Wittig
Journal:  Clin Orthop Relat Res       Date:  2008-09-18       Impact factor: 4.176

4.  Surgical treatment of giant cell tumour of long bone with anhydrous alcohol adjuvant.

Authors:  Joo Han Oh; Pil Whan Yoon; Sang Hoon Lee; Hwan Seong Cho; Woo Sung Kim; Han-Soo Kim
Journal:  Int Orthop       Date:  2006-05-31       Impact factor: 3.075

5.  Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Authors:  Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

6.  Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy.

Authors:  F Malek; P Krueger; Z N Hatmi; A A Malayeri; H Faezipour; R J O'Donnell
Journal:  Int Orthop       Date:  2006-08-02       Impact factor: 3.075

7.  The Most Appropriate Reconstruction Method Following Giant Cell Tumor Curettage: A Biomechanical Approach.

Authors:  Azadeh Ghouchani; Mohammad H Ebrahimzadeh; Gholamreza Rouhi
Journal:  Arch Bone Jt Surg       Date:  2018-03

8.  Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Authors:  Richard D Lackman; Eileen A Crawford; Joseph J King; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2008-11-06       Impact factor: 4.176

9.  Treatment of giant cell tumor of bone: Current concepts.

Authors:  Ajay Puri; Manish Agarwal
Journal:  Indian J Orthop       Date:  2007-04       Impact factor: 1.251

10.  Curettage of benign bone tumors without grafts gives sufficient bone strength.

Authors:  Takashi Yanagawa; Hideomi Watanabe; Tetsuya Shinozaki; Kenji Takagishi
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.